    William Plovanic | | ZoomInfo.com    William Plovanic | Canaccord Genuity Corp | ZoomInfo.com

Bizapedia.com - Human Validation
















COMPANIESPEOPLEPRODUCTS/SERVICESTRADEMARKSADDRESSESPHONE BOOK




            Our system has detected a high number of page requests from your IP Address, please prove to us that you are a human to continue using our website.
        
























                            Please send me to the search subscription offer page after I successfully answer the word challenge.
                        









BIZAPEDIAPRO SEARCHPerform unlimited searches via ouradvanced search form withBizapedia Pro Search.FIND OUT MORE >BIZAPEDIAPRO DATABuild custom data listsfor one or many stateswith Bizapedia Pro Data.FIND OUT MORE >


Copyright © 2012-2017 · Bizapedia.com · All rights reserved.BlogPro SearchPro APIContact UsTerms of UsePrivacy PolicySitemapDesktop Version















William J Plovanic - Wilmette, IL | Intelius



























Sign In



We found William J Plovanic in Wilmette, IL


William J Plovanic

                                                                           Intelius found that William J Plovanic  is  a male between 40 and 50 years old from Wilmette, IL.  We have connected them to
                14 addresses,
                14 phones,
                and 5 relatives or associates.
         





Also Known As

William P Plovanic
William S Plovanic


Get Report Now

Age

William J Plovanic is in his 40s

William Has Lived In

Wilmette, IL
Chicago, IL
Boston, MA

William's Relatives

Vincente Plovanic
Colleen Lindberg
Thomas Plovanic
Stephan Plovanic







William J Plovanic



Zodiac SignPisces



GenderMale



Professional Status
Managing Director at Canaccord Adams Inc.



Get Report Now










Want to know more about William? Get a comprehensive background report, find full phone numbers, and other contact information when available, all from billions of available public records.
            Continue below for more details about William, or use our people search engine to find others.
Get Background Check on William J Plovanic
Get a Criminal Check on William J Plovanic
Get a Public Record Report on William J Plovanic
Get a People Search Report on William J Plovanic


William J Plovanic's Contact Information
Known Cities Lived In
Find out where William J Plovanic has lived as well as William J Plovanic's phone numbers and email addresses.




William J Plovanic Has Lived in 5 States
Illinois Address for William J Plovanic


210 C****** P*** A** 

Wilmette, IL


Has Lived In

Wilmette, IL
Chicago, IL


Get Full Address Report










Phone Numbers Associated with William J Plovanic

(847) ***-**** - Wilmette, IL 
(847) ***-**** - Evanston, IL 
(617) ***-**** - Albany, NY 


Get Full Phone Report



Email Addresses Associated with William J Plovanic

w*******c@***.com
w*******c@***.com
w**************c@***.com


Get Email Report




William J Plovanic's Professional Information
Information regarding William J Plovanic's professional history.  Find out previous places William J Plovanic has worked as well as dates employed.
            The following data is not guaranteed for accuracy and should not be used for employment, insurance, credit eligibility, or for any other purpose covered under the Fair Credit Reporting Act.


William J Plovanic Has Worked at 3 Places
Company: Canaccord Adams Inc.
               Title: Managing Director
Company: FA Technology Ventures L.P
               Title: Executive
William J Plovanic's Experience
Title: Managing Director
               Company: Canaccord Adams Inc.
Job Details
               Company Size: Less than $1 mil - Employee Range: Less than 25
Title: Executive
               Company: FA Technology Ventures L.P
Job Details
               Company Size: Less than $1 mil - Employee Range: Less than 25
Additional Professional Information on William J Plovanic

 See William J Plovanic's LinkedIn Profile



William J Plovanic's Social Network and Potential Email Matches
Find out potential social network profiles and potential email usernamed for William J Plovanic


William J Plovanic's known Social Networks And Potential Email Matches

Find all of William J Plovanic's Social Network Profiles

Get Full Report

Search Social Networks
Including Facebook, LinkedIn, MySpace, Google, Twitter, Yahoo, Jigsaw, ZoomInfo and more



Potential Email Matches
William Plovanic
Username Matches

                  WilliamPlovanic
                  PlovanicWilliam
                  William.Plovanic
                  Plovanic.William
                  William_Plovanic
                  Plovanic_William
                  William-Plovanic
                  Plovanic-William
                  WPlovanic
               


Popular Email Services

@gmail.com
@aol.com
@yahoo.com
@comcast.net
@hotmail.com
@msn.com
@rocketmail.com
@att.net
@sbcglobal.net
@ymail.com
@facebook.com
@mail.com
@bellsouth.net
@live.com
@earthlink.net
@cox.net
@prodigy.net
@me.com
@peoplepc.com
@juno.com
@rediffmail.com
@mindspring.com
@comcast.com
@charter.net
@outlook.com




All trademarks, product names, company names or logos on this page are the property of their respective owners.
Related People Searches
W Plovanic







         Intelius is a leading provider of public data about people and their connections to others. Intelius does not provide consumer reports and is not a consumer reporting agency as defined by the Fair Credit Reporting Act (FCRA). This site should not be used to determine an individual’s eligibility for credit, insurance, employment, housing or any other purpose covered by the FCRA. For employment or tenant screening services, please visit our partner Talentwise.
      

About Us
Site Map
About Our Reports
Blog
Help
Contact Us

© 2003 – 2017 PeopleConnect, Inc. d/b/a Intelius. All Rights Reserved.
         Privacy Policy - UPDATED
Terms of Service - UPDATED






What is the FCRA?
The Fair Credit Reporting Act ("FCRA") is a federal law that promotes the accuracy, fairness and privacy of information in the files of consumer reporting agencies.
Intelius does not provide consumer reports and is not a consumer reporting agency as defined by the FCRA. Intelius reports cannot be used for background checks related to consumer credit, insurance, employment, housing or any other purpose
                  prohibited under the FCRA.
You may not use any information obtained from Intelius for any purpose covered by the FCRA.
Find out more about the FCRA here.













William Plovanic, Obalon Therapeutics Inc: Profile & Biography - Bloomberg


































































  


























Feedback





William Plovanic

Chief Financial Officer,
Obalon Therapeutics Inc






Career History




Chief Financial Officer
Obalon Therapeutics Inc, 3/2016-PRESENT


Mng Dir:Equity Research
Canaccord Genuity Corp, 2/2007-3/2016


Analyst
Investec Inc, 9/1999-2001


Analyst
First Albany Capital Inc, 3/2001-UNKNOWN


Show More









Website:
www.obalon.com






Corporate Information
Address:

5421 Avenida Encinas
Suite F
Carlsbad, CA 92008-4410
United States


Phone:
1-760-607-5151


Fax:
-


Web url:
www.obalon.com











From The Web












Personal Information



Education



Bradley University
Bachelor's Degree, Finance








Awards & Publications



Awards




ALL-STAR ANALYST, WALL STREET JOURNAL, Medical Device sector, 2004




ALL-STAR ANALYST, WALL STREET JOURNAL, Medical Device sector, 2003






Certificates




Chartered Financial Analyst (CFA)









Memberships



Other Memberships




Investment Analysts Society of Chicago(Iasc)


Member




Association for Investment Management And Research(Aimr)


Member









Sponsored Financial Commentaries







More From The Web


















Home


News


Top Headlines
Most Popular
Exclusive
Law
Entrepreneurs
Leaders
Economy
Environment
Science
Sports
Markets Magazine
Pursuits Magazine
Bloomberg Visual Data
Bloomberg Best (and Worst)
For comments or complaints about news coverage click here


Regions
U.S.
China
Europe
Asia
U.K. & Ireland
Australia & New Zealand
Canada
India & Pakistan
Japan
Africa
Eastern Europe
Latin America
Middle East
Markets
Commodities
Currencies
Bonds
Stocks
Energy Markets
Municipal Bonds
Emerging Markets
Funds
Islamic Finance
Industries
Energy
Technology
Real Estate
Finance
Health Care
Transportation
Insurance
Retail
Media
Manufacturing




Quick


Market Data


Stocks
Stock Futures
World Indexes
Americas
Europe, Middle East, & Africa
Asia-Pacific
Gainers & Losers
Earnings Calendar
Industry Leaders
Currencies
Americas
Europe, Middle East, & Africa
Asia-Pacific
Foreign Exchange Cross Rates
FX Fixings
Currency Converter
Forex Trading Videos
Commodities
Energy Prices
Metals Prices
Agricultural Prices


Rates & Bonds
US Treasuries
UK Gilts
Germany Bunds
Japan Bonds
Australia Bonds
Bloomberg Bond Indexes
Corporate Bonds
Consumer Rates
Economic Calendar
Watchlist
European Debt Crisis
Symbol Search
The Market Now




Personal Finance


Top Headlines
Saving & Investing
Real Estate
Retirement Planning
Financial Advisers
Taxes
Blog: Ventured & Gained
Real Cost Of
Money Gallery
Calculators
Watchlist (Portfolio Tracker)




Tech


Top Headlines
Social Media
Mobile & Wireless
Web
Enterprise Tech
TV, Games & Movies
Apple
Tech Deals
Global Tech
Slideshows
Videos




U.S. Politics


Sustainability


Top Headlines
Energy
Corporate Sustainability
Policy
Natural Resources
Health & Population
Slideshows
Videos
Blog: The Grid




Luxury


Top Headlines
Autos
Billionaires
Living
Property
Travel
Well Spent
Loot Blog
Pursuits Magazine
Videos




TV


Live TV
Channel Finder
Personalities
Apple TV
iPad App
Schedule
U.S.
Asia
Europe


Shows
Surveillance
Market Makers
Lunch Money
Street Smart
Bloomberg West
Game Changers




Video


Must See
Latest
Live TV
Shows
Playlist




Radio


Live Radio
Shows
Schedule
Personalities
Podcasts
Bloomberg Brief
Featured Podcasts and New Shows
Bloomberg View
Masters in Business
First Word
Surveillance
Bloomberg Advantage
In the Loop
Bloomberg Law
Taking Stock
Bloomberg Best
More Podcasts




Blogs


Global Tech
The Grid
Loot
The Market Now
Political Capital
Tech Deals
Ventured and Gained




Opinion




My Saved



Registration



Sign In



Bloomberg.com



Businessweek.com



Company



About
Blog
Careers
Diversity & Inclusion
News Mission
Philanthropy & Engagement
Press Room
Procurement
Sustainability




Products



Financial Products
Bloomberg Professional Service
Bloomberg Anywhere
Bloomberg Tradebook
Bloomberg Briefs
Bloomberg Indexes
Bloomberg SEF
Service Center
Customer Support
Enterprise Products
Enterprise Solutions
Trading Solutions
Industry Products
Bloomberg BNA
Bloomberg Government
Bloomberg Law
Bloomberg Link
Bloomberg New Energy Finance
Bloomberg Sports
Content Licensing




Bloomberg Anywhere



Mobile Apps



Bloomberg Visual Data






































 - 



























































                      NEWS HOME
                    

Advertising
Board and Executive Moves
Energy
Health Care
Hedge Funds
M & A
Private Equity
Technology








            You have  
            
9 free profiles

              left this month   
			      

                Start Your Free Trial ➤
              








            Hey, we noticed you're a RelSci Pro subscriber! Would you like to view the page there?
            

                View on RelSci Pro ➤
              




























































































































Email







LinkedIn







Facebook







Google+







Tweet







Reddit





Permalink










Overview
Paths








 Overview




 Paths to 








 You



 Connections via Relationship Science



 






Sync your contacts to see how you can connect with .

Start My Free Trial ➤








See  More 


 



You've reached your 10 free profiles limit this month.
Upgrade to RelSci Pro today to enjoy unlimited article views and much more!

Start My Free Trial  ➤

Still not convinced? Check out our full listing of features here.












Are you a RelSci Pro Subscriber?

Login to RelSci Pro 
                        ➤


Not a Pro Subscriber? Log in here to manage your alerts









 Keep me signed in.
        

Login  ➤



        Forgot your Password?
    

























 I have read the LexisNexis terms & conditions




Sign Me Up  ➤
















Microsoft personalized ad preferences




 













To opt out of personalized ads in this browser, your browser history must allow first-party and third-party cookies and you must have your browsing experience set to NOT delete browsing history on exit. Instructions for enabling cookies and configuring your browsing history may be available in your browsers settings, privacy, or help documentation.

















Sign in
















  Hold on… We’re sorry but this didn’t work.                  You can’t turn off personalized ads right now because your browser is currently blocking third-party cookies. We can help you fix this issue.                Let’s get started:  Depending on what browser you use, open Options or Settings.                  Make sure that third-party cookies are not blocked anymore. To find out how, search your browser’s Help.                                 Revisit http://choice.microsoft.com/opt-out, and then on the “Personalized ads in this browser” tile, click Off.                 ext74081 




  About Our Ads To create a more customized online experience, some of the ads you may receive on Microsoft websites and apps are tailored to your previous activities, searches and site visits. You're in control and here's where you can make the advertising choice that's right for you. ext74075 




  Where Can I Learn More about Advertising on Microsoft Websites and Apps? Microsoft partners with Oath, AppNexus and other third party service providers to help present customized content and display advertisements on MSN, Outlook.com and other websites and apps. Microsoft also delivers search ads to Bing and our search syndication partners. Learn more about Microsoft’s privacy practices here. You can learn more about interest-based ads from Oath and AppNexus in their privacy statements: Oath and AppNexus. What Choices Do I Have About Interest-Based Advertising? On this page, you can opt out of receiving interest based advertising from Microsoft. You can also opt out of receiving interest-based advertising from all self-regulatory members, including Microsoft, Oath, AppNexus and other third party ad networks, at the following sites:  In the US: Digital Advertising Alliance (DAA) In Europe: European Interactive Digital Advertising Alliance (EDAA) In Canada: Ad Choices: Digital Advertising Alliance of Canada (DAAC)  You can control interest-based advertising in Windows apps by turning off the advertising ID in Windows Settings.  More choices  Do you want personalized ads from other companies?  Questions? If you have a privacy question or a question for the Chief Privacy Officer of Microsoft, please contact us by using our web form. We will respond to questions within 30 days. ext74076 




       Personalized ads in this browser     OFF    Opt-out is currently unavailable, please try again later.  Control the "personalized ads" setting for this web browser.  Learn more           If you want Microsoft to show ads that might be relevant to you, click On. To show “generic” ads, click Off.          ext74078 




       Personalized ads wherever I use my Microsoft account     OFF   Sign in to change...    Opt-out is currently unavailable, please try again later.  Control the "personalized ads" setting that applies when you are signed in on any computer or device with your Microsoft account, including Windows, Windows phone, Xbox and other devices.  Learn more                    If you want Microsoft to show ads that might be relevant to you, click On. To show “generic” ads, click Off.         If you choose “generic” ads and use a browser, your choice applies to everyone when using that browser as long as you do not clear your cookies.          ext74079 




       Personalized ads in Windows         In your Windows Settings, you can turn off personalized ads that appear in apps on this device. You’ll still see ads, but they won’t be personalized anymore.     If you have Windows 8.1:            Access the charms by touching or moving your pointer to the right edge of the screen.                 Click or tap Settings, and then click or tap Change PC Settings.                 Click or tap Privacy, and then turn off Let apps use my advertising ID for experiences across apps.          If you have Windows 10:            Click or tap the Start button.                 Click or tap Settings.                 Click or tap Privacy, and then turn off Let apps use my advertising ID for experiences across apps.          If you have a Windows mobile device:            Go to Settings.                 Tap on Privacy.                 Tap on Advertising ID, and then turn off Let apps use my advertising ID for experiences across apps.                If you want to turn off personalized ads from Microsoft wherever you use your Microsoft account including apps on Windows, Windows Phone, Xbox and other devices, you can do so by selecting the Microsoft account option above.    ext74080 














Legal
Privacy & Cookies
© 2017 Microsoft















Orthopedics & Neurotechnology Companies: William Plovanic - First Albany Corporation - The Wall Street Transcript














































 






































Healthcare >> Analyst Interviews >> May 19, 2003 Orthopedics & Neurotechnology Companies: William Plovanic – First Albany Corporation
WILLIAM J. PLOVANIC is a managing director and senior research analyst
at First Albany Capital, covering medical technology. Mr. Plovanic
joined First Albany Capital in March 2001, after serving as a research
analyst covering medical devices and products at PMG Capital. Prior to
PMG, he was the director of research for the Capital Markets Division of
LaSalle St. Securities, Inc. in Chicago, where he was responsible for
management of the research department, in addition to coverage of the
small cap healthcare technology and biotechnology industries. He began
his career as a diversified healthcare analyst with Madison Securities,
Inc., in Chicago. In 2003 and 2004 Mr. Plovanic was selected as a Wall
Street Journal 'All Star' Analyst in the medical device sector and was
named the number one ranked analyst by Starmine for stock picking and
performance in the medical technology sector for 2002. He graduated from
Bradley University with a BS in Finance. He is a CFA charter holder  and
is a member of both the Association for Investment Management and
Research and the Investment Analysts Society of Chicago.  sector -
medical devices Profile


TWST: What's your coverage in the orthopedics area?Mr. Plovanic: I currently cover 10 orthopedic companies and threeneurotechnology names. I also cover Medtronic (MDT), which I don'tinclude
    

Join for free to read a longer excerpt or purchase this article

Already a member? Login here 









CartLatest NewsAll American USC Footbal Player Joseph M. Boskovich Jr. Now Picks All American Value Stocks for his ClientsPaul Hogan Picks Tech Dividend Growers Microchip Technology (NASDAQ:MCHP), Xilinx (NASDAQ:XLNX) and Versum Materials (NYSE:VSM)600 Gallons of Water to Produce a McDonalds (NYSE:MCD) Quarter Pounder:  How Will Investors Profit?The Wall Street Transcript is a completely unique resource for investors and business researchers.Over 20,000 CEO, Equity Analyst and Money Manager InterviewsSubscribe now!Sign Up For Newsletter Weekly email with New In-Depth Interviews


Email: 



Most Popular InterviewsBuilding Diversified Portfolios with Quality Global EquitiesGregory D. PadillaAlberto Jimenez Crespo Published July 27, 2017 in Investing StrategiesCompanies covered: AMZN 005930 AAPL MU WHR KIMBERA GS VOD PPG SHW VIV PEY Buy ($25)Building Accountability and Avoiding Mistakes Through the Decision ProcessDean  Pagonis Published July 27, 2017 in Investing StrategiesCompanies covered: CMP SBH AMZN ULTA CVS LRLCY KMB WWW SDF Buy ($25)Finding Optimal Balance Sheets by Utilizing High Yield Market ExpertiseZach  Miller Published July 27, 2017 in Investing StrategiesCompanies covered: LSXMK SIRI BLL CHTR ARMK Buy ($25)Most Popular ReportsInvesting Strategies Published July 24, 2017Buy ($175)Wireless Communications & Telecom Published July 14, 2017Buy ($175)Investing Strategies Published July 11, 2017Buy ($175) 






Top Company Interviews






Register for a Free Account to gain greater access to
            The Wall Street Transcript right now




CEO INTERVIEWSInterview with the President and CEO: Lumos Networks Corp. (NASDAQ:LMOS)Interview with the Corporate VP of Business Development, Strategy and Investor Relations: DSP Group, Inc. (NASDAQ:DSPG)Interview with the CEO and Director: Tactile Systems Technology, Inc. (NASDAQ:TCMD) 

SECTOR ROUNDTABLESNatural Gas Weighs Heavy On E&P Near-Term ProspectsRoundtable Forum:optimism Despite Uncertainty In For-profit EducationRoundtable Forum:a Shift In Focus To Natural Gas From Oil 

MONEY MANAGER INTERVIEWSBuilding Diversified Portfolios with Quality Global EquitiesBuilding Accountability and Avoiding Mistakes Through the Decision ProcessFinding Optimal Balance Sheets by Utilizing High Yield Market Expertise 

ANALYST INTERVIEWSAnalyzing the Secular Drivers Within Communications Infrastructure and TelecomSatellite Companies Benefiting from Growth in Data TrafficIncreased Focus on Content as Consumers Shift to Digital Consumption 




Subscribe Today!







                Since 1963
                © The Wall Street Transcript 1997-2016
Terms and Conditions
Privacy Policy  
            





https://www.twst.com/wp-admin/admin-ajax.php

Pin It on Pinterest





































Share This





Twitter





Facebook





Google+





Gmail





LinkedIn








































×





Join now for free!
Already a member?






First Name 





Last Name 





Email address *








Create new account
 


or create an account with a social network.

Join with Facebook


Join with Twitter


Join with Google








Username or Email address: *





Password: *






LoginJoin now! | Forgot password?
 


or login using a social network


Log in with Facebook


Log in with Twitter


Log in with Google

















News on Unknown Bucket Name


























































                      NEWS HOME
                    

Advertising
Board and Executive Moves
Energy
Health Care
Hedge Funds
M & A
Private Equity
Technology















                                Person                            


                                    William J. Plovanic                                    ▼





                                Topic                            


                                    All Topics                                    ▼








Organizations

                                Find news about organizations
                            





Alumni

                                Find news on alumni of any org
                            





Industries

                                Find news on a particular market
                            





Your Contacts

                                Find news on your contacts
                            








Sign up for free daily alerts on this feed:











By pressing Sign Up, you agree to our Terms of Use, Privacy Policy, and the LexisNexis Terms & Conditions


















Follow




                            Change Feed
                        


Unknown Bucket Name











Obalon Schedules Second Quarter 2017 Financial Results Conference Call for August 2, 2017 at 8:30 a.m. Eastern Time


                                July 27, 2017                                 • 
                                GlobeNewswire                            


                                  ... For more information, please visitÂ www.obalon.com. For Obalon Therapeutics, Inc. Investor Contact: William Plovanic Chief Financial Officer Obalon Therapeutics, Inc. Office: +1 760 607 5103 ...
                                









Obalon Receives Regulatory Approvals to Commercialize in Select Middle East Markets


                                May 11, 2017                                 • 
                                GlobeNewswire                            


                                  ... or circumstances after the date hereof. For Obalon Therapeutics, Inc. Investor Contact: William Plovanic Chief Financial Officer Obalon Therapeutics, Inc. Office: +1 760 607 5103 ...
                                









Obalon Announces First Quarter 2017 Financial Results


                                May 10, 2017                                 • 
                                GlobeNewswire                            


                                  ... accounts payable $ 129 $ €” For Obalon Therapeutics, Inc. Investor Contact: William Plovanic Chief Financial Officer Obalon Therapeutics, Inc. Office: +1 760 607 5103 ...
                                









Obalon Therapeutics, Inc. Announces Fourth Quarter and Full Year 2016 Financial Results


                                February 23, 2017                                 • 
                                GlobeNewswire                            


                                  ... in accounts payable $ 140 $ For Obalon Therapeutics, Inc. Investor Contact: William Plovanic Chief Financial Officer Obalon Therapeutics, Inc. Office: +1 760 607 5103 ...
                                









Obalon Therapeutics Inc Announces Fourth Quarter and Year End 2016 Financial Results Conference Call


                                February 15, 2017                                 • 
                                GlobeNewswire                            


                                  ... For more information, please visit www.obalon.com. For Obalon Therapeutics Inc. Investor Contact: William Plovanic Chief Financial Officer Obalon Therapeutics, Inc. Office: +1 760 607 5103 ...
                                









Obalon Therapeutics Inc Announces Fourth Quarter and Year End 2016 Financial Results Conference Call


                                February 15, 2017                                 • 
                                GlobeNewswire                            


                                  ... excellence. For more information, please visit�www.obalon.com. For Obalon Therapeutics Inc. Investor Contact: William Plovanic Chief Financial Officer Obalon Therapeutics, Inc. Office: +1 760 607 5103 ...
                                









Obalon Therapeutics Inc. (Nasdaq: OBLN) to Ring The Nasdaq Stock Market Closing Bell


                                January 18, 2017                                 • 
                                GlobeNewswire                            


                                  ... 3:45 p.m. to 4:00 p.m. ET Obalon Contact:Fiona Farley(646) 517-20Obalon@evolvemkd.com Investor Contact:William J Plovanic, CFO(760) 607-5103wplovanic@obalon.com Nasdaq MarketSite:Emily Pan(646) 441-5120emily.pan@nasdaq.com Feed Information:Fiber Line (Encompass Waterfront): ...
                                









Obalon Announces Initial Commercial Patient Placements of the First and Only Swallowable, FDA-Approved Balloon System for Weight Loss


                                January 13, 2017                                 • 
                                GlobeNewswire                            


                                  ... statements to reflect events or circumstances after the date hereof. Investor Contact: William Plovanic Chief Financial Officer Obalon Therapeutics, Inc. Office: +1 760 607 5103 ...
                                









Obalon Therapeutics To Present at Two Upcoming Investor Conferences


                                November 14, 2016                                 • 
                                GlobeNewswire                            


                                  ... of financial and clinical excellence. For more information, please visit�www.obalon.com.� Investor Contact: William Plovanic Chief Financial Officer Obalon Therapeutics, Inc. Office: +1 760 607 5103 ...
                                









Obalon Therapeutics Announces Third Quarter Financial Results


                                November 11, 2016                                 • 
                                GlobeNewswire                            


                                  ... � � � � � � For Obalon Therapeutics Inc. Investor Contact: William Plovanic Chief Financial Officer Obalon Therapeutics, Inc. Office: +1 760 607 5103 ...
                                









Obalon Therapeutics Announces Pricing of Initial Public Offering


                                October 5, 2016                                 • 
                                GlobeNewswire                            


                                  ... qualification under the securities laws of any such state or jurisdiction. Contact: William Plovanic, CFO Obalon Therapeutics, Inc. Office 760.607.5103 wplovanic@obalon.com Megan Driscoll, CEO evolveMKD ...
                                









EYE ON EQUITIES : STOCKS THAT SHOULD BE ON YOUR RADAR SCREEN


                                October 7, 2015                                 • 
                                The Globe and Mail (Canada)                            


                                  ... focus of investors, even if revenue doesn't meet expectations, Canaccord Genuity analyst William Plovanic said. He upgraded the stock to "buy" from "hold." Target: Mr. ...
                                









Just the right fit:ConforMIS is going after a bigger share of the $15 billion joint replacement market, starting with custom-shaped knees


                                August 18, 2015                                 • 
                                The Boston Globe                            


                                  ... & Johnson's DePuy Synthes, and Smith & Nephew — according to William J. Plovanic, medical device analyst for investment bank Canaccord Genuity in Evanston, Ill. ...
                                









What analysts are saying: New coverage for Entellus Medical, Famous Dave's


                                February 28, 2015                                 • 
                                Star Tribune (Minneapolis, Minnesota)                            


                                  ... an "overweight" rating and a 12-month price target of $25 per share. William Plovanic of Canaccord Genuity Corp. started his coverage with a "buy" rating ...
                                







Related News Feeds






Obalon Therapeutics, Inc.







Medical Products & Equipment







Board and Executive Moves in Medical Products & Equipment







Alumni of Bradley University

























































































































Email







LinkedIn







Facebook







Google+







Tweet







Reddit





Permalink



 






Want to see the full history of news or view news on a particular date? Upgrade to RelSci Professional now!


Start My Free Trial  ➤










 Industry:




 Select a Topic:



 Keyword:



Go  ➤









 Find an Organization:






 Select a Topic:




 Keyword:




Go  ➤









 Find a Person:






 Select a Topic:




 Keyword:




Go  ➤









 Name of a School:







 Or Name of an Organization:









 Select a Topic:




 Keyword:




Go  ➤








Thank you. You are now subscribed.Please wait for the page to refresh...










You are now subscribed to this feed.










You have unsubscribed to this feed.










Thank you. You can now subscribe to more RelSci news feeds.










 To subscribe to more than one feed, please enter a password.




 Please confirm your password



Go  ➤








You've found a premium RelSci Pro feature!



Follow News On Your Contacts

Upgrade to RelSci Pro now to easily sync your contacts and stay in the know on the news about the people important to you.


Start My Free Trial  ➤

Still not convinced? Check out our full listing of features here.



Not Now








You've found a premium RelSci Pro feature!



Search News On Keywords

Curate your news even further with the ability to filter feeds based on specific keywords mentioned in the articles.


Start My Free Trial  ➤

Still not convinced? Check out our full listing of features here.



Not Now













Industries

                        Find news on a particular market
                    





People

                        Find news about people
                    





Organizations

                        Find news about organizations
                    





Alumni

                        Find news on alumni of any org
                    





Your Contacts

                        Find news on your contacts
                    












                Free Daily Alerts
            


                Sign up for free daily alerts on this feed
            




Sign Up ➤

                    By pressing Sign Up, you agree to our Terms of Use, Privacy Policy, and the LexisNexis Terms & Conditions




                Already have an account?  Click here to login.















Are you a RelSci Pro Subscriber?

Login to RelSci Pro 
                        ➤


Not a Pro Subscriber? Log in here to manage your alerts









 Keep me signed in.
        

Login  ➤



        Forgot your Password?
    

























 I have read the LexisNexis terms & conditions




Sign Me Up  ➤


















 































William J. Plovanic | Benzinga

















Benzinga


Benzinga Pro


Marketfy


Financial Data & APIs


Fintech Awards


Premarket Prep







Membership is FreeWhat are you waiting for? Sign up now!
Username: 


Username available!Username taken!
Email: 


Email available!Email taken!
Password: 



Leave blank: 




OR




Free Account Login
Click here to access your premium account

Username or email: 



Password: 




OR

Forgot password?'

Looking for



?

CLICK HERE




  Contribute Login Sign up  

 
 
 


Benzinga - Feed Your Mind.












HomeBest of Benzinga
Careers
About
Contact Us
Partners
Benzinga Fintech Awards

NewsEarnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Retail Sales
Offerings
IPOs
Insider Trades
Biotech/FDA

MarketsPre-Market
After Hours
Movers
Forex
Commodities
Options
Binary Options
Bonds
Futures
Global Economics
Previews
Reviews
Small-Cap

RatingsAnalyst Color
Downgrades
Upgrades
Initiations
Price Target

IdeasLong Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
ETFs

TechStart-Ups

Fintech
Personal Finance
Marketfy
Benzinga Pro

















Market Overview















TickersArticlesKeywordsSearch by keyword...googlecse


 



 
 




            William J. Plovanic          



Home
Top Stories
News
Ratings
Ideas
Options
Forex
ETFs
Media
Economics
Press Releases
Latest Stories
Store
Better Manage Your Personal Finances
premarket.benzinga.com



 











NuVasive Upgraded To Buy At Canaccord On Leverage
Tuesday, October 6, 2015 - 8:08am
Analyst Color, Canaccord Genuity, NUVA, William J. Plovanic, Upgrades, Price Target, Analyst Ratings


      

		NuVasive, Inc (NASDAQ: NUVA) shares are up 46 percent in the last one year, rising to their 52-week high of $56.61 on August 4.

		Canaccord Genuity’s William J. Plovanic upgraded the rating on the company from Hold to Buy, while raising the price target from $52 to $58.

		The company...    
Read More >>




UPDATE: Canaccord Genuity Initiates Coverage On Intersect ENT On Expanded Market Opportunity
Monday, March 16, 2015 - 8:54am
Analyst Color, Canaccord Genuity, William J. Plovanic, XENT, Initiation, Analyst Ratings


      In a report published Monday, Canaccord Genuity analyst William J. Plovanic initiated coverage on Intersect ENT Inc. (NASDAQ: XENT) with a Buy rating and $27.00 price target.
In the report, Canaccord Genuity noted, "Intersect's strong clinical data profile has proven the efficacy of its PROPEL and...    
Read More >>




UPDATE: Canaccord Genuity Initiates Coverage on MiMedx Group on Potential of New Segment
Friday, October 4, 2013 - 11:33am
Analyst Color, Canaccord Genuity, MDXG, William J. Plovanic, Initiation, Analyst Ratings


      In a report published Friday, Canaccord Genuity analyst William J. Plovanic initiated coverage on MiMedx Group (NASDAQ: MDXG) with a Buy rating and $6.00 price target.

In the report, Canaccord Genuity noted, “By our estimates, the dermal substitute segment of the advanced wound care market...    
Read More >>




UPDATE: Canaccord Genuity Downgrades Solta Medical Following CEO Change, Lowered Guidance
Wednesday, August 7, 2013 - 11:21am
Analyst Color, Canaccord Genuity, SLTM, William J. Plovanic, Downgrades, Analyst Ratings


      
	In a report published Wednesday, Canaccord Genuity analyst William J. Plovanic downgraded Solta Medical (NASDAQ: SLTM) from Buy to Hold, and lowered the price target from $3.50 to $2.50.

	In the report, Canaccord Genuity noted, “We are lowering our rating to HOLD from Buy. While Q2/13 was mixed...    
Read More >>




UPDATE: Canaccord Genuity Downgrades RTI Surgical Following In-Line Revenue, Lowered Guidance
Wednesday, August 7, 2013 - 11:06am
Analyst Color, Canaccord Genuity, RTIX, William J. Plovanic, Downgrades, Analyst Ratings


      
	In a report published Wednesday, Canaccord Genuity analyst William J. Plovanic downgraded RTI Surgical (NASDAQ: RTIX) from Buy to Hold, and lowered the price target from $5.00 to $3.50.

	In the report, Canaccord Genuity noted, “We are downgrading our rating to HOLD from Buy following an in-line...    
Read More >>




UPDATE: Canaccord Genuity Raises PT on Insulet Following Investor Conference
Monday, June 24, 2013 - 10:38am
Analyst Color, Canaccord Genuity, PODD, William J. Plovanic, Price Target, Analyst Ratings


      
	In a report published Monday, Canaccord Genuity analyst William J. Plovanic reiterated a Buy rating on Insulet (NASDAQ: PODD), and raised the price target from $28.00 to $37.00.

	In the report, Canaccord Genuity noted, “We are reiterating our BUY rating on shares of Insulet. Management has...    
Read More >>




UPDATE: Canaccord Genuity Raises PT on Dexcom on Multiple Catalysts Ahead
Monday, June 24, 2013 - 10:14am
Analyst Color, Canaccord Genuity, DXCM, William J. Plovanic, Price Target, Analyst Ratings


      
	In a report published Monday, Canaccord Genuity analyst William J. Plovanic reiterated a Buy rating on DexCom (NASDAQ: DXCM), and raised the price target from $19.00 to $25.00.

	In the report, Canaccord Genuity noted, “We reiterate our BUY rating. We believe commercialization of the G4 Platinum...    
Read More >>




UPDATE: Canaccord Genuity Raises PT on NuVasive on Multiple Positive Factors
Wednesday, June 19, 2013 - 11:11am
Analyst Color, Canaccord Genuity, NUVA, William J. Plovanic, Price Target, Analyst Ratings


      
	In a report published Wednesday, Canaccord Genuity analyst William J. Plovanic reiterated a Buy rating on NuVasive (NASDAQ: NUVA), and raised the price target from $24.50 to $29.00.

	In the report, Canaccord Genuity noted, “We reiterate our BUY rating and are positioning NuVasive as our top new...    
Read More >>




Canaccord Genuity Reiterates Buy Rating on Globus Medical Following Synthes Legal Verdict
Monday, June 17, 2013 - 12:22pm
Analyst Color, Canaccord Genuity, GMED, William J. Plovanic, Reiteration, Analyst Ratings


      
	In a report published Monday, Canaccord Genuity analyst William J. Plovanic reiterated a Buy rating and $22.00 price target on Globus Medical (NYSE: GMED).

	In the report, Canaccord Genuity noted, “We reiterate our BUY rating following a negative ruling in the company's patent infringement...    
Read More >>



 
 







 










        Newsletter & Alerts
      










          Become a Wall-Street Wizard.
        




Market in 5 Minutes
Everything you need to know about the market - quick & easy.





Daily Analyst Rating
A summary of each day’s top rating changes from sell-side  analysts on the street.





FinTech Focus
Yesterday’s biggest gainers and losers. As well as 10 stocks to keep an eye on for Today






TERMS & CONDITIONS





Thank You
for registering for Benzinga’s newsletters and alerts.



            • The Daily Analysts Ratings email will be received daily between 7am and 10am.
          

            • The Market in 5 Minutes email will be received daily between 7am and 8am.
          

            • The Fintech Focus email will be received every Friday between 2pm and 5pm.
          


          If you have any questions as it relates to either of the three newsletters, please feel free to contact us at  1-877-440-ZING.
        









Trending
Recent








1
AMD: Citi Still Selling AMD, Concerned About Profitability


2
OEC, X: 20 Stocks Moving In Wednesday's Pre-Market Session


3
AXTI, CYH: 20 Stocks Moving In Thursday's Pre-Market Session


4
PFE, AZN: Why Is AstraZeneca Sinking Today?


5
AAPL, VZ: Gilead Sciences, Verizon Communications, And M...


6
DAL, AMZN: Jim Cramer Shares His Thoughts On Del...


7
NFLX, GOOGL: The JPMorgan Mid-Day Note...

 





1
SBUX, CVX: 10 Stocks To Watch For July 28, 2017


2
Economic Data Scheduled For Friday


3
PNM, AAL: Earnings Scheduled For July 28, 2017


4
INTC, SNAP: Watch These 5 Huge Put Purchases In Friday Trade


5
HTZ, TWTR: Watch These 4 Huge Call Purchases In Friday Trade


6
SPY, OSTK: Exclusive: Overstock CEO Thinks He...


7
TWTR: Trump's Transgender Ban Fe...

 






 



 



 



 








          Benzinga is a fast-growing, dynamic and innovative financial media outlet that empowers investors with high-quality, unique content.
        





Popular ChannelsAnalyst Ratings
Be Your Own Boss
ETFs
Economics
Forex
Hot
News
Options
Press Releases
Start-ups
Tech
Tools & FeaturesAffiliate Program
PreMarket Prep
Feeds
News Widget
Real Time Feed
Sitemap
Submit News Tips
About BenzingaAbout Us
Licensing and APIs
Apps (iOS and Android)
Fintech Awards
Blog
Syndication
In the News
Careers
Service Status
Contact Us
Disclaimer
Privacy Policy
Terms and Conditions


Benzinga Partners
 


 


1 (877) 440-9464 (ZING)
© Copyright Benzinga

























